Importantly, aberrant type I IFN and neutrophil responses are hallmarks of non-resolving pulmonary TB despite antibiotic therapy68, and these patients may especially benefit from adjunctive PARP1 inhibition. Here, PARP1 is linked to pulmonary tuberculosis.